Opinion|Videos|August 1, 2024
Economic Impact of IPF
Author(s)Justin Oldham, MD, MS
The panel explores how IPF affects patient productivity and its contribution to the disease's overall economic burden.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the impact of IPF on patient productivity and how does this contribute to the overall economic burden of the disease?
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Multi-Hit TP53 Linked to Shorter Survival in Chronic-Phase MPN Cohorts
4
Navigating GLP-1 Access & Prior Authorizations: Amanda Velazquez, MD
5